Skip to main content
NVDA+0.34%AAPL+0.11%GOOGL+0.93%MSFT+0.09%AMZN+0.16%TSM-0.16%SPCX+1.09%META+0.06%AVGO-1.10%TSLA-0.17%SKHY-1.36%MU+0.15%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.26%AUDUSD-1.12%AUDJPY-1.05%GBPCHF+1.01%USDCHF+0.85%GBPCAD+0.77%CHFJPY-0.72%EURGBP-0.66%GBPNZD+0.66%USDCAD+0.64%EURAUD+0.61%AUDNZD-0.59%USDTHB+0.54%NZDUSD-0.54%CADJPY-0.54%EURUSD-0.53%AUDCAD-0.51%EURJPY-0.44%NZDJPY-0.43%GBPTRY+0.41%GBPHKD+0.32%NZDCHF+0.32%EURCHF+0.31%AUDCHF-0.30%GBPMXN-0.28%USDTRY+0.27%GBPJPY+0.23%CADCHF+0.21%USDCNH-0.21%USDILS+0.16%GBPUSD+0.14%EURCAD+0.11%NZDCAD+0.11%USDJPY+0.09%USDMXN+0.08%NZDMXN+0.06%USDCOP-0.04%USDHKD+0.03%NZDSGD-0.03%USDZAR+0.03%SGDJPY+0.03%USDSGD-0.03%GBPSGD-0.02%AUDSGD-0.02%EURNZD+0.02%EURSGD-0.01%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%EURNOK0.00%USDSEK0.00%USDPLN0.00%EURHKD0.00%EURDKK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURPLN0.00%GBPZAR0.00%PLNJPY0.00%EURSEK0.00%USDDKK0.00%USDNOK0.00%XNGUSD+0.43%USOIL-0.36%XPTUSD-0.31%HG1-0.15%XAGUSD+0.07%GAGUSD+0.06%XAUUSD-0.02%GAUUSD-0.02%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.19%ETHUSD+7.44%USDTUSD-0.01%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.95%ZECUSDT+1.00%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT-0.23%XLMUSD+2.38%BCHUSDT-0.19%UNIUSD0.00%LTCUSD+0.07%HBARUSDT+3.35%SUIUSD+1.80%TONUSD+15.77%TAOUSDT+0.94%AAVEUSD-3.34%DOTUSDT+3.96%ICPUSDT-2.94%ONDOUSDT-0.05%WLDUSDT+10.92%ARBUSDT+0.37%JUPUSDT+0.41%ATOMUSDT+1.22%INJUSDT-2.12%STXUSDT+18.96%FETUSDT+2.37%SEIUSDT+1.69%PYTHUSDT-1.64%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.28%OPUSDT+0.54%WIFUSDT+3.87%IOTAUSDT+3.72%POLUSDT-4.19%AXSUSDT+0.24%FARTCOINUSDT+0.04%EOSUSDT+5.02%DYDXUSDT+4.95%GALAUSDT+6.11%ORDIUSDT+1.28%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.34%AAPL+0.11%GOOGL+0.93%MSFT+0.09%AMZN+0.16%TSM-0.16%SPCX+1.09%META+0.06%AVGO-1.10%TSLA-0.17%SKHY-1.36%MU+0.15%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.26%AUDUSD-1.12%AUDJPY-1.05%GBPCHF+1.01%USDCHF+0.85%GBPCAD+0.77%CHFJPY-0.72%EURGBP-0.66%GBPNZD+0.66%USDCAD+0.64%EURAUD+0.61%AUDNZD-0.59%USDTHB+0.54%NZDUSD-0.54%CADJPY-0.54%EURUSD-0.53%AUDCAD-0.51%EURJPY-0.44%NZDJPY-0.43%GBPTRY+0.41%GBPHKD+0.32%NZDCHF+0.32%EURCHF+0.31%AUDCHF-0.30%GBPMXN-0.28%USDTRY+0.27%GBPJPY+0.23%CADCHF+0.21%USDCNH-0.21%USDILS+0.16%GBPUSD+0.14%EURCAD+0.11%NZDCAD+0.11%USDJPY+0.09%USDMXN+0.08%NZDMXN+0.06%USDCOP-0.04%USDHKD+0.03%NZDSGD-0.03%USDZAR+0.03%SGDJPY+0.03%USDSGD-0.03%GBPSGD-0.02%AUDSGD-0.02%EURNZD+0.02%EURSGD-0.01%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%EURNOK0.00%USDSEK0.00%USDPLN0.00%EURHKD0.00%EURDKK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURPLN0.00%GBPZAR0.00%PLNJPY0.00%EURSEK0.00%USDDKK0.00%USDNOK0.00%XNGUSD+0.43%USOIL-0.36%XPTUSD-0.31%HG1-0.15%XAGUSD+0.07%GAGUSD+0.06%XAUUSD-0.02%GAUUSD-0.02%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.19%ETHUSD+7.44%USDTUSD-0.01%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.95%ZECUSDT+1.00%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT-0.23%XLMUSD+2.38%BCHUSDT-0.19%UNIUSD0.00%LTCUSD+0.07%HBARUSDT+3.35%SUIUSD+1.80%TONUSD+15.77%TAOUSDT+0.94%AAVEUSD-3.34%DOTUSDT+3.96%ICPUSDT-2.94%ONDOUSDT-0.05%WLDUSDT+10.92%ARBUSDT+0.37%JUPUSDT+0.41%ATOMUSDT+1.22%INJUSDT-2.12%STXUSDT+18.96%FETUSDT+2.37%SEIUSDT+1.69%PYTHUSDT-1.64%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.28%OPUSDT+0.54%WIFUSDT+3.87%IOTAUSDT+3.72%POLUSDT-4.19%AXSUSDT+0.24%FARTCOINUSDT+0.04%EOSUSDT+5.02%DYDXUSDT+4.95%GALAUSDT+6.11%ORDIUSDT+1.28%NOTUSDT+1.55%RONINUSDT+0.06%
UT

United Therapeutics Corporation (UTHR)

NASDAQ • Healthcare

$541.89
+$60.41 (+12.5%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$482.2
Day Range$475.46 - $557.37
Avg. Volume (3M)871.8K
Market Cap$23B
P/E Ratio17.9
52 Week Range
$409.07$609.35
Next EarningsIn 35 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$783.3M100%
Gross Profitminus cost of goods$683.8M87%
Operating Incomeminus R&D and overhead$330.8M42%
Net Incomeminus taxes and the rest$333M43%

In plain terms: out of every $100 in revenue, United Therapeutics Corporation keeps $43 as net profit.

Fundamentals & Financials

Revenue (TTM)
$3.1B
Net Income (TTM)
$1.3B
EPS (TTM)
$30.23
ROA (TTM)
18.16%
Current Ratio
5.73

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+8.0%Q1 2026$7.7
-16.9%Q2 2026$5.82
+6.0%Q3 2026$7.27
Next

Nov 4

in 35 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +6.0%

United Therapeutics' adjusted EPS topped consensus even as revenue missed, as the company posted fiscal second-quarter 2026 results on Aug. 5. Revenue fell 1.9% to about $783.3 million from about $798.6 million a year ago, and it came in below the $804.6 million estimate by about -2.7%; gross margin held near 87% and operating margin was about 42%, with operating income at roughly $330.8 million. The lower revenue did not stop net income from increasing 7.6% to about $333.0 million from about $309.5 million a year ago, and adjusted EPS of $7.27 topped the $6.86 estimate by about 6% and rose 13.4% from $6.41 a year ago. Operating cash flow reached about $776.9 million. Consensus for the next period calls for adjusted EPS of $7.03 on revenue of $800.2 million.

View full earnings history

About United Therapeutics Corporation

United Therapeutics Corporation is a NASDAQ-listed biotechnology company focused on discovering, developing, and bringing to market therapies for chronic and severe illnesses, especially pulmonary hypertension and certain cancers. Its portfolio spans marketed medicines and pipeline programs, and it generated $3.2 billion of revenue in FY2025.

Name
United Therapeutics Corporation
CEO
Martine A. Rothblatt
Website
www.unither.com
Industry
Healthcare
Year Founded
1996
Employees
1,400

Today's Snapshot

AI-generated

UTHR closed 12.6% above yesterday's close, outperforming a weaker sector. Trading was unusually busy, with volume roughly three times its usual level. United Therapeutics won a court ruling that rival drugmaker Liquidia infringed two patents.

Trading Volume

Above 10d avg 1.1M

3.2M

vs S&P 500 Today

Strong Outperformance

+12.36%

Updated: September 30, 2026 at 20:08 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
UTHR is rated Strong Buy as the stock is trading well above its short-, medium- and long-term moving averages with clear momentum supporting the advance. CCI and simple momentum readings are strongly positive and on-balance volume is constructive, while the pivot level lies far below the current price, underscoring bullish positioning. ADX shows a moderate trend strength and ATR indicates contained volatility, although the price sits above the Bollinger upper band suggesting near-term extension. Technical takeaway: Strong Buy — broad-based upside confirmed by moving averages and volume, albeit with signs of short-term extension.
All signals
  • EMA (5 indicators)$497.17 - $519.04
    Buy
  • RSI (14)65.71
    Neutral
  • Stochastic %K (14, 3, 3)51.23
    Neutral
  • MACD Level (12, 26)-3.70
    Neutral

Peers & Related Assets

WATWaters Corporation
$439.39-0.9%
ILMNIllumina, Inc.
$273.68+0.6%
BIIBBiogen Inc.
$225.88-0.5%
WSTWest Pharmaceutical Services, Inc.
$370.76-1.6%
RPRXRoyalty Pharma plc
$58.36+0.2%
DGXQuest Diagnostics Incorporated
$233.07+0.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.